<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01112670</url>
  </required_header>
  <id_info>
    <org_study_id>09-0531</org_study_id>
    <secondary_id>R03DK084089</secondary_id>
    <nct_id>NCT01112670</nct_id>
  </id_info>
  <brief_title>The Role of P-glycoprotein in Sitagliptin Clinical Pharmacology</brief_title>
  <official_title>The Role of P-glycoprotein in Sitagliptin Clinical Pharmacology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the pharmacogenetics, pharmacokinetics, and
      drug-drug interactions of sitagliptin therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sitagliptin Monotherapy: Sitagliptin Area Under the Plasma Concentration-time Curve (AUC) From 0 to Infinity</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sitagliptin Monotherapy: Sitagliptin Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sitagliptin Monotherapy: Sitagliptin Renal Clearance (CLr)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sitagliptin + Atorvastatin: Sitagliptin Area Under the Plasma Concentration-time Curve (AUC) From 0 to Infinity</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sitagliptin + Atorvastatin: Sitagliptin Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sitagliptin + Atorvastatin: Sitagliptin Renal Clearance (CLr)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24 hours post-dose</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Relative Change in Sitagliptin Area Under the Plasma Concentration-time Curve (AUC) From 0 to Infinity</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24 hours post-dose</time_frame>
    <description>AUC of sitagliptin when administered with atorvastatin divided by AUC of sitagliptin when administered alone</description>
  </other_outcome>
  <other_outcome>
    <measure>Relative Change in Sitagliptin Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24 hours post-dose</time_frame>
    <description>Cmax of sitagliptin when administered with atorvastatin divided by Cmax of sitagliptin when administered alone</description>
  </other_outcome>
  <other_outcome>
    <measure>Relative Change in Sitagliptin Renal Clearance (CLr)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24 hours</time_frame>
    <description>CLr of sitagliptin when administered with atorvastatin divided by CLr of sitagliptin when administered alone</description>
  </other_outcome>
  <other_outcome>
    <measure>Atorvastatin Area Under the Plasma Concentration Time Curve (AUC) Over the Dosing Interval (0-24 Hours)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24 hours post-dose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Atorvastatin Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24 hours post-dose</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ABCB1 Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABCB1 CGC/CGC genetic make-up; sitagliptin 100 mg x 1 dose; atorvastatin 40 mg x 5 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABCB1 Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABCB1 CGC/TTT genetic make-up; sitagliptin 100 mg x 1 dose; atorvastatin 40 mg x 5 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABCB1 Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABCB1 TTT/TTT genetic make-up; sitagliptin 100 mg x 1 dose; atorvastatin 40 mg x 5 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>sitagliptin 100 mg x 1 dose</description>
    <arm_group_label>ABCB1 Group 1</arm_group_label>
    <arm_group_label>ABCB1 Group 2</arm_group_label>
    <arm_group_label>ABCB1 Group 3</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>atorvastatin 40 mg x 5 doses</description>
    <arm_group_label>ABCB1 Group 1</arm_group_label>
    <arm_group_label>ABCB1 Group 2</arm_group_label>
    <arm_group_label>ABCB1 Group 3</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men and women between 21 to 60 years of age will be recruited to participate
             in this study.

          -  Subjects will be eligible if metabolic, renal, hepatic, and hematological laboratory
             tests are within normal limits.

        Exclusion Criteria:

          -  Subjects will be excluded from the study if they have a current or past history of
             cardiovascular, hepatic, endocrine (e.g., diabetes), renal, pancreatic,
             gastrointestinal, pulmonary, immunologic, hematologic, or neurologic disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina L Aquilante, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2010</study_first_submitted>
  <study_first_submitted_qc>April 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2010</study_first_posted>
  <results_first_submitted>October 7, 2012</results_first_submitted>
  <results_first_submitted_qc>December 4, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 8, 2013</results_first_posted>
  <last_update_submitted>January 22, 2013</last_update_submitted>
  <last_update_submitted_qc>January 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Krestin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy volunteers were recruited from the Denver metro area between November 2009 and December 2010.</recruitment_details>
      <pre_assignment_details>Participants (n=145) were genetically pre-screened for ABCB1 1236/2677/3435 diplotypes. Those who possessed the needed ABCB1 genetic diplotypes, along with requisite clinical inclusion criteria, were started in the study (n=33).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ABCB1 Group 1</title>
          <description>ABCB1 CGC/CGC genetic make-up. Sitagliptin to Sitagliptin+Atorvastatin. 8 participants started. 7 participants completed.</description>
        </group>
        <group group_id="P2">
          <title>ABCB1 Group 1*</title>
          <description>ABCB1 CGC/CGC genetic make-up. Sitagliptin+Atorvastatin to Sitagliptin. 3 participants started. 3 participants completed.</description>
        </group>
        <group group_id="P3">
          <title>ABCB1 Group 2</title>
          <description>ABCB1 CGC/TTT genetic make-up. Sitagliptin to Sitagliptin+Atorvastatin. 7 participants started. 6 participants completed.</description>
        </group>
        <group group_id="P4">
          <title>ABCB1 Group 2*</title>
          <description>ABCB1 CGC/TTT genetic make-up. Sitagliptin+Atorvastatin to Sitagiptin. 4 participants started. 4 participants completed.</description>
        </group>
        <group group_id="P5">
          <title>ABCB1 Group 3</title>
          <description>ABCB1 TTT/TTT genetic make-up. Sitagliptin to Sitagliptin+Atorvastatin. 6 participants started. 5 participants completed.</description>
        </group>
        <group group_id="P6">
          <title>ABCB1 Group 3*</title>
          <description>ABCB1 TTT/TTT genetic make-up. Sitagliptin+Atorvastatin to Sitagliptin. 5 participants started. 5 participants completed.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Sitagliptin to Sitagliptin+Atorvastatin</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Sitagliptin+Atorvastatin to Sitagliptin</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Study Population</title>
          <description>All participants who participated in at least one period of the study (n=33)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sitagliptin Monotherapy: Sitagliptin Area Under the Plasma Concentration-time Curve (AUC) From 0 to Infinity</title>
        <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24 hours post-dose</time_frame>
        <population>The population analyzed included participants who completed both periods of the pharmacokinetic crossover study.</population>
        <group_list>
          <group group_id="O1">
            <title>ABCB1 Group 1</title>
            <description>ABCB1 CGC/CGC genetic make-up</description>
          </group>
          <group group_id="O2">
            <title>ABCB1 Group 2</title>
            <description>ABCB1 CGC/TTT genetic make-up</description>
          </group>
          <group group_id="O3">
            <title>ABCB1 Group 3</title>
            <description>ABCB1 TTT/TTT genetic make-up</description>
          </group>
        </group_list>
        <measure>
          <title>Sitagliptin Monotherapy: Sitagliptin Area Under the Plasma Concentration-time Curve (AUC) From 0 to Infinity</title>
          <population>The population analyzed included participants who completed both periods of the pharmacokinetic crossover study.</population>
          <units>ng*hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3638" spread="1439"/>
                    <measurement group_id="O2" value="3502" spread="1133"/>
                    <measurement group_id="O3" value="3129" spread="795"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.83</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sitagliptin Monotherapy: Sitagliptin Maximum Plasma Concentration (Cmax)</title>
        <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24 hours post-dose</time_frame>
        <population>The population analyzed included participants who completed both periods of the pharmacokinetic crossover study.</population>
        <group_list>
          <group group_id="O1">
            <title>ABCB1 Group 1</title>
            <description>ABCB1 CGC/CGC genetic make-up</description>
          </group>
          <group group_id="O2">
            <title>ABCB1 Group 2</title>
            <description>ABCB1 CGC/TTT genetic make-up</description>
          </group>
          <group group_id="O3">
            <title>ABCB1 Group 3</title>
            <description>ABCB1 TTT/TTT genetic make-up</description>
          </group>
        </group_list>
        <measure>
          <title>Sitagliptin Monotherapy: Sitagliptin Maximum Plasma Concentration (Cmax)</title>
          <population>The population analyzed included participants who completed both periods of the pharmacokinetic crossover study.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="454" spread="180"/>
                    <measurement group_id="O2" value="438" spread="152"/>
                    <measurement group_id="O3" value="394" spread="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.67</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sitagliptin + Atorvastatin: Sitagliptin Area Under the Plasma Concentration-time Curve (AUC) From 0 to Infinity</title>
        <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24 hours post-dose</time_frame>
        <population>The population analyzed included participants who completed both periods of the pharmacokinetic crossover study.</population>
        <group_list>
          <group group_id="O1">
            <title>ABCB1 Group 1</title>
            <description>ABCB1 CGC/CGC genetic make-up</description>
          </group>
          <group group_id="O2">
            <title>ABCB1 Group 2</title>
            <description>ABCB1 CGC/TTT genetic make-up</description>
          </group>
          <group group_id="O3">
            <title>ABCB1 Group 3</title>
            <description>ABCB1 TTT/TTT genetic make-up</description>
          </group>
        </group_list>
        <measure>
          <title>Sitagliptin + Atorvastatin: Sitagliptin Area Under the Plasma Concentration-time Curve (AUC) From 0 to Infinity</title>
          <population>The population analyzed included participants who completed both periods of the pharmacokinetic crossover study.</population>
          <units>ng*h/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3501" spread="1617"/>
                    <measurement group_id="O2" value="3430" spread="1279"/>
                    <measurement group_id="O3" value="3117" spread="1216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.90</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sitagliptin + Atorvastatin: Sitagliptin Maximum Plasma Concentration (Cmax)</title>
        <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24 hours post-dose</time_frame>
        <population>The population analyzed included participants who completed both periods of the pharmacokinetic crossover study.</population>
        <group_list>
          <group group_id="O1">
            <title>ABCB1 Group 1</title>
            <description>ABCB1 CGC/CGC genetic make-up</description>
          </group>
          <group group_id="O2">
            <title>ABCB1 Group 2</title>
            <description>ABCB1 CGC/CGC genetic make-up</description>
          </group>
          <group group_id="O3">
            <title>ABCB1 Group 3</title>
            <description>ABCB1 TTT/TTT genetic make-up</description>
          </group>
        </group_list>
        <measure>
          <title>Sitagliptin + Atorvastatin: Sitagliptin Maximum Plasma Concentration (Cmax)</title>
          <population>The population analyzed included participants who completed both periods of the pharmacokinetic crossover study.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="428" spread="201"/>
                    <measurement group_id="O2" value="420" spread="137"/>
                    <measurement group_id="O3" value="370" spread="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.56</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Relative Change in Sitagliptin Area Under the Plasma Concentration-time Curve (AUC) From 0 to Infinity</title>
        <description>AUC of sitagliptin when administered with atorvastatin divided by AUC of sitagliptin when administered alone</description>
        <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24 hours post-dose</time_frame>
        <population>The population analyzed included participants who completed both periods of the pharmacokinetic crossover study.</population>
        <group_list>
          <group group_id="O1">
            <title>ABCB1 Group 1</title>
            <description>ABCB1 CGC/CGC genetic make-up</description>
          </group>
          <group group_id="O2">
            <title>ABCB1 Group 2</title>
            <description>ABCB1 CGC/TTT genetic make-up</description>
          </group>
          <group group_id="O3">
            <title>ABCB1 Group 3</title>
            <description>ABCB1 TTT/TTT genetic make-up</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change in Sitagliptin Area Under the Plasma Concentration-time Curve (AUC) From 0 to Infinity</title>
          <description>AUC of sitagliptin when administered with atorvastatin divided by AUC of sitagliptin when administered alone</description>
          <population>The population analyzed included participants who completed both periods of the pharmacokinetic crossover study.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" lower_limit="0.81" upper_limit="1.11"/>
                    <measurement group_id="O2" value="0.98" lower_limit="0.88" upper_limit="1.07"/>
                    <measurement group_id="O3" value="0.97" lower_limit="0.87" upper_limit="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.97</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Relative Change in Sitagliptin Maximum Plasma Concentration (Cmax)</title>
        <description>Cmax of sitagliptin when administered with atorvastatin divided by Cmax of sitagliptin when administered alone</description>
        <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24 hours post-dose</time_frame>
        <population>The population analyzed included participants who completed both periods of the pharmacokinetic crossover study.</population>
        <group_list>
          <group group_id="O1">
            <title>ABCB1 Group 1</title>
            <description>ABCB1 CGC/CGC genetic make-up</description>
          </group>
          <group group_id="O2">
            <title>ABCB1 Group 2</title>
            <description>ABCB1 CGC/TTT genetic make-up</description>
          </group>
          <group group_id="O3">
            <title>ABCB1 Group 3</title>
            <description>ABCB1 TTT/TTT genetic make-up</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change in Sitagliptin Maximum Plasma Concentration (Cmax)</title>
          <description>Cmax of sitagliptin when administered with atorvastatin divided by Cmax of sitagliptin when administered alone</description>
          <population>The population analyzed included participants who completed both periods of the pharmacokinetic crossover study.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" lower_limit="0.75" upper_limit="1.17"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.79" upper_limit="1.21"/>
                    <measurement group_id="O3" value="0.93" lower_limit="0.76" upper_limit="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.86</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sitagliptin Monotherapy: Sitagliptin Renal Clearance (CLr)</title>
        <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24 hours post-dose</time_frame>
        <population>The population analyzed included participants who completed both periods of the pharmacokinetic crossover study and who had complete urine data.</population>
        <group_list>
          <group group_id="O1">
            <title>ABCB1 Group 1</title>
            <description>ABCB1 CGC/CGC genetic make-up</description>
          </group>
          <group group_id="O2">
            <title>ABCB1 Group 2</title>
            <description>ABCB1 CGC/TTT genetic make-up</description>
          </group>
          <group group_id="O3">
            <title>ABCB1 Group 3</title>
            <description>ABCB1 TTT/TTT genetic make-up</description>
          </group>
        </group_list>
        <measure>
          <title>Sitagliptin Monotherapy: Sitagliptin Renal Clearance (CLr)</title>
          <population>The population analyzed included participants who completed both periods of the pharmacokinetic crossover study and who had complete urine data.</population>
          <units>ml/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="254" spread="176"/>
                    <measurement group_id="O2" value="232" spread="62"/>
                    <measurement group_id="O3" value="359" spread="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.21</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sitagliptin + Atorvastatin: Sitagliptin Renal Clearance (CLr)</title>
        <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24 hours post-dose</time_frame>
        <population>The population analyzed included participants who completed both periods of the pharmacokinetic crossover study and who had complete urine data.</population>
        <group_list>
          <group group_id="O1">
            <title>ABCB1 Group 1</title>
            <description>ABCB1 CGC/CGC genetic make-up</description>
          </group>
          <group group_id="O2">
            <title>ABCB1 Group 2</title>
            <description>ABCB1 CGC/TTT genetic make-up</description>
          </group>
          <group group_id="O3">
            <title>ABCB1 Group 3</title>
            <description>ABCB1 TTT/TTT genetic make-up</description>
          </group>
        </group_list>
        <measure>
          <title>Sitagliptin + Atorvastatin: Sitagliptin Renal Clearance (CLr)</title>
          <population>The population analyzed included participants who completed both periods of the pharmacokinetic crossover study and who had complete urine data.</population>
          <units>ml/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="280" spread="124"/>
                    <measurement group_id="O2" value="226" spread="66"/>
                    <measurement group_id="O3" value="339" spread="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Relative Change in Sitagliptin Renal Clearance (CLr)</title>
        <description>CLr of sitagliptin when administered with atorvastatin divided by CLr of sitagliptin when administered alone</description>
        <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24 hours</time_frame>
        <population>The population analyzed included participants who completed both periods of the pharmacokinetic crossover study and who had complete urine data.</population>
        <group_list>
          <group group_id="O1">
            <title>ABCB1 Group 1</title>
            <description>ABCB1 CGC/CGC genetic make-up</description>
          </group>
          <group group_id="O2">
            <title>ABCB1 Group 2</title>
            <description>ABCB1 CGC/TTT genetic make-up</description>
          </group>
          <group group_id="O3">
            <title>ABCB1 Group 3</title>
            <description>ABCB1 TTT/TTT genetic make-up</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change in Sitagliptin Renal Clearance (CLr)</title>
          <description>CLr of sitagliptin when administered with atorvastatin divided by CLr of sitagliptin when administered alone</description>
          <population>The population analyzed included participants who completed both periods of the pharmacokinetic crossover study and who had complete urine data.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" lower_limit="0.97" upper_limit="1.48"/>
                    <measurement group_id="O2" value="0.99" lower_limit="0.82" upper_limit="1.16"/>
                    <measurement group_id="O3" value="1.0" lower_limit="0.81" upper_limit="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Atorvastatin Area Under the Plasma Concentration Time Curve (AUC) Over the Dosing Interval (0-24 Hours)</title>
        <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24 hours post-dose</time_frame>
        <population>The population analyzed included participants who completed both periods of the pharmacokinetic crossover study.</population>
        <group_list>
          <group group_id="O1">
            <title>ABCB1 Group 1</title>
            <description>ABCB1 CGC/CGC genetic make-up</description>
          </group>
          <group group_id="O2">
            <title>ABCB1 Group 2</title>
            <description>ABCB1 CGC/TTT genetic make-up</description>
          </group>
          <group group_id="O3">
            <title>ABCB1 Group 3</title>
            <description>ABCB1 TTT/TTT genetic make-up</description>
          </group>
        </group_list>
        <measure>
          <title>Atorvastatin Area Under the Plasma Concentration Time Curve (AUC) Over the Dosing Interval (0-24 Hours)</title>
          <population>The population analyzed included participants who completed both periods of the pharmacokinetic crossover study.</population>
          <units>ng*h/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4" spread="28.0"/>
                    <measurement group_id="O2" value="35.4" spread="35.6"/>
                    <measurement group_id="O3" value="49.0" spread="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.29</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Atorvastatin Maximum Plasma Concentration (Cmax)</title>
        <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24 hours post-dose</time_frame>
        <population>The population analyzed included participants who completed both periods of the pharmacokinetic crossover study.</population>
        <group_list>
          <group group_id="O1">
            <title>ABCB1 Group 1</title>
            <description>ABCB1 CGC/CGC genetic make-up</description>
          </group>
          <group group_id="O2">
            <title>ABCB1 Group 2</title>
            <description>ABCB1 CGC/TTT genetic make-up</description>
          </group>
          <group group_id="O3">
            <title>ABCB1 Group 3</title>
            <description>ABCB1 TTT/TTT genetic make-up</description>
          </group>
        </group_list>
        <measure>
          <title>Atorvastatin Maximum Plasma Concentration (Cmax)</title>
          <population>The population analyzed included participants who completed both periods of the pharmacokinetic crossover study.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="6.2"/>
                    <measurement group_id="O2" value="7.5" spread="7.6"/>
                    <measurement group_id="O3" value="10.6" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.43</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Pharmacokinetic study periods</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Overall Study Population</title>
          <description>All participants who started the study (n=33)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pain at IV site</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased liver function tests</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Findings are only applicable to individuals with ABCB1 CGC/CGC, CGC/TTT, or TTT/TTT diplotypes.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Christina Aquilante, Pharm.D.</name_or_title>
      <organization>University of Colorado</organization>
      <phone>303-724-6126</phone>
      <email>christina.aquilante@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

